Tags : Progress

ViiV’s PROgress Study Demonstrates Inclusion of PROs into Clinical Practice

Tuba Khan November 19, 2020

Shots: In the PROgress study, 200 people living with HIV were provided with a pre-visit survey to guide their conversation with their HCP and assess PROs covering a range of […]readmore

DigiHealth

IBM Watson Health Reports Real-World Progress of AI in Oncology

Vartika Singh June 5, 2019

Shots: IBM Watson has presented 22 new scientific studies showing progress in clinical studies of cancer using AI-Technology with informed decisions based on curated scientific evidences, insights and information which […]readmore

Tags : Progress

ViiV’s PROgress Study Demonstrates Inclusion of PROs into Clinical Practice

IBM Watson Health Reports Real-World Progress of AI in Oncology

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Progress

ViiV’s PROgress Study Demonstrates Inclusion of PROs into Clinical Practice

IBM Watson Health Reports Real-World Progress of AI in Oncology

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company